| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Covid Antigen, Sars COV 2
MessageRapid (15 Minute) Antigen Testing will now be available to select CRMC ED patients to facilitate throughput. Testing will be used for admitted patients who are waiting to be placed in an open bay area and have a COVID PCR test pending. Antigen testing is less precise than PCR for detecting COVID, but the quick turnaround can aid in timely patient placement.
Antigen testing will also be available as a POC option in some Procedure areas and for Employee Health.
Antigen testing will also be available as a POC option in some Procedure areas and for Employee Health.
Test Code
COVAG
Preferred Specimen
Nasal Swab
Instructions
CRMC ED PROCESS:
1.Obtain Nasal Specimen Collection Kit from the STAT Lab
2. Wash your hand
3.Wear appropriate PPE, gown, gloves
4. Insert the swab 1/2 -3/4 of an inch into nostrile and swirl 5 x
5. Insert same Swab into other nostrile and repeat.
6. Place swab into the dry, sterile container (provided in Collection Kit)
7. Place patient label on sterile container
8. Return specimen to Stat Lab immediately.
1.Obtain Nasal Specimen Collection Kit from the STAT Lab
2. Wash your hand
3.Wear appropriate PPE, gown, gloves
4. Insert the swab 1/2 -3/4 of an inch into nostrile and swirl 5 x
5. Insert same Swab into other nostrile and repeat.
6. Place swab into the dry, sterile container (provided in Collection Kit)
7. Place patient label on sterile container
8. Return specimen to Stat Lab immediately.
Procedure areas and EH follow you POC Policy |
|||
Specimen Stability
- Swabs in the kit are approved for use with BinaxNOW COVID-19 Ag Card. Do not use other swabs.
- Do not store or test specimens in viral transport media, as it may result in false positive or false negative results
- Do not store the swab after specimen collection in the original paper packaging, if storage is needed use a plastic tube with cap.
- For best performance, direct nasal swabs should be tested as soon as possible after collection.
- If immediate testing is not possible, and to maintain best performance and avoid possible contamination, it is highly recommended the nasal swab is placed in a clean, unused plastic tube labeled with patient information, preserving sample integrity, and capped tightly at room temperature (15-30°C) for up to (1) hour prior to testing. Ensure the swab fits securely within the tube and the cap is tightly closed.
- If greater than 1 hour delay occurs, dispose of sample. A new sample must be collected for testing.
Methodology
Binax Now: Covid-19 Antigen
Setup Schedule
24x7
Reference Range
Negative
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in nasal swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.
Negative results from patients with symptom onset beyond seven days, should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures,history and the presence of clinical signs and symptoms consistent with COVID-19
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in nasal swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.
Negative results from patients with symptom onset beyond seven days, should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures,history and the presence of clinical signs and symptoms consistent with COVID-19
Clinical Significance
For the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection. Positive results indicate the presence of viral antigens. This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens. Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARSCoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.
Performing Laboratory
CRMC Laboratory
POC -Proceedure areas
POC-EH
